Fig. 5: IRAK1 expression correlated with poor prognosis and IRAK1 promoted the progression of glioma. | Cell Death & Disease

Fig. 5: IRAK1 expression correlated with poor prognosis and IRAK1 promoted the progression of glioma.

From: The m6A reader HNRNPC promotes glioma progression by enhancing the stability of IRAK1 mRNA through the MAPK pathway

Fig. 5

A TCGA assessment of the expression levels of IRAK1 in normal and glioma tissues. B ROC curve indicating the diagnostic value of IRAK1 in glioma. C Kaplan–Meier OS plot showing survival rates for glioma patients with low expression (red) or high expression (blue) of IRAK1 in the TCGA and CGGA databases (two-sided log-rank test). D Representative images of IHC staining for IRAK1 protein expression in two TMAs (HBraG125PG01 and HBraG155Su01) with three normal brain, 203 grade I-III glioma, and 74 GBM tissues. E Summary of the IRAK1 protein expression profile in (D). IHC staining score: 0, negative; 0–60, weak; 60–150, moderate, 150–300 strong. F Kaplan–Meier OS plot showing survival rates for glioma patients with low expression (red) or high expression (blue) of IRAK1 in the TMA HBraG155Su01 (two-sided log-rank test). G Western blot analysis demonstrating the efficiency of the IRAK1 knockdown. H, I, J MTS, EdU, and colony-formation assays were conducted to evaluate the effect on proliferative ability by regulating IRAK1 expression. K, L Transwell and wound-healing assays were performed to evaluate the effect on invasion and migration abilities by regulating IRAK1 expression. Data are shown as the mean ± SD of three replicates; *p < 0.05, **p < 0.01, ***p < 0.001, compared with the negative control group.

Back to article page